News November 16, 2023 PHM finds transformative cancer diagnostics and treatments are underutilized in employer health benefit programs PHM, a clinically sophisticated healthcare navigation firm specializing in serious and complex conditions, reveals a significant gap in the provision of cutting-edge cancer diagnostics and treatments within the U.S. employer population. PHM’s … Read More
Case Studies November 16, 2023 Breaking through a borderline cancer diagnosis We met Maggie*, a vibrant 41-year-old mother of two young children, soon after she was diagnosed with stage 2 breast cancer. Determined to find the best possible treatment path, Maggie’s family reached … Read More
Ask Our Experts November 16, 2023 Breakthroughs in liver cancer screening and treatment Primary liver cancer is one of the deadliest cancers globally, with a five-year survival rate of 20%.1 It is also one of the most quickly increasing types of cancer in the U.S,2 … Read More
Ask Our Experts November 16, 2023 FDA approves Zepbound™, another new obesity drug The blockbuster weight loss drugs Wegovy® and Ozempic® have been in the news for much of the past year. This past April, we posted an article about these drugs, explaining the basics … Read More
Published Research November 16, 2023 Why every employer needs a molecular profiling strategy PHM, a clinically sophisticated healthcare navigation firm specializing in serious and complex conditions, reveals a significant gap in the provision of cutting-edge cancer diagnostics and treatments within the U.S. employer population. PHM’s … Read More
Ask Our Experts November 16, 2023 Popular nasal decongestant doesn’t work. What now? Based on a review of new data, an FDA panel concluded that a common decongestant, phenylephrine, is not effective for the relief of nasal congestion symptoms when taken orally (pill or liquid) … Read More
